MAFLD: Renovation of clinical practice and disease awareness of fatty liver

Recently, international expert panels have proposed a new definition of fatty liver: metabolic dysfunction‐associated fatty liver disease (MAFLD). MAFLD is not just a simple renaming of non‐alcoholic fatty liver disease (NAFLD). The unique feature of MAFLD is the inclusion of metabolic dysfunctions,...

Full description

Saved in:
Bibliographic Details
Published inHepatology research Vol. 52; no. 5; pp. 422 - 432
Main Authors Kawaguchi, Takumi, Tsutsumi, Tsubasa, Nakano, Dan, Torimura, Takuji
Format Journal Article
LanguageEnglish
Published Netherlands Wiley Subscription Services, Inc 01.05.2022
Subjects
Atherosclerosis
atherosclerotic cardiovascular disease
Clinical medicine
Clinical trials
disease awareness
Fatty liver
hepatic fibrosis
Liver diseases
metabolic‐associated fatty liver
Metabolism
Risk factors
steatosis
metabolic-associated fatty liver
atherosclerotic cardiovascular disease
disease awareness
hepatic fibrosis
steatosis
Online AccessGet full text

Cover

Abstract Recently, international expert panels have proposed a new definition of fatty liver: metabolic dysfunction‐associated fatty liver disease (MAFLD). MAFLD is not just a simple renaming of non‐alcoholic fatty liver disease (NAFLD). The unique feature of MAFLD is the inclusion of metabolic dysfunctions, which are high‐risk factors for events. In addition, MAFLD is independent of alcohol intake and the co‐existing causes of liver disease. This new concept of MAFLD may have a widespread impact on patients, medical doctors, medical staff, and various stakeholders regarding fatty liver. Thus, MAFLD may renovate clinical practice and disease awareness of fatty liver. In this review, we introduce the definition of and rationale for MAFLD. We further describe representative cases showing how the diagnostic processes differ between MAFLD and NAFLD. We also summarize recent studies comparing MAFLD with NAFLD and discuss the impact of MAFLD on clinical trials, Japanese populations, and disease awareness.
AbstractList Recently, international expert panels have proposed a new definition of fatty liver: metabolic dysfunction-associated fatty liver disease (MAFLD). MAFLD is not just a simple renaming of non-alcoholic fatty liver disease (NAFLD). The unique feature of MAFLD is the inclusion of metabolic dysfunctions, which are high-risk factors for events. In addition, MAFLD is independent of alcohol intake and the co-existing causes of liver disease. This new concept of MAFLD may have a widespread impact on patients, medical doctors, medical staff, and various stakeholders regarding fatty liver. Thus, MAFLD may renovate clinical practice and disease awareness of fatty liver. In this review, we introduce the definition of and rationale for MAFLD. We further describe representative cases showing how the diagnostic processes differ between MAFLD and NAFLD. We also summarize recent studies comparing MAFLD with NAFLD and discuss the impact of MAFLD on clinical trials, Japanese populations, and disease awareness.Recently, international expert panels have proposed a new definition of fatty liver: metabolic dysfunction-associated fatty liver disease (MAFLD). MAFLD is not just a simple renaming of non-alcoholic fatty liver disease (NAFLD). The unique feature of MAFLD is the inclusion of metabolic dysfunctions, which are high-risk factors for events. In addition, MAFLD is independent of alcohol intake and the co-existing causes of liver disease. This new concept of MAFLD may have a widespread impact on patients, medical doctors, medical staff, and various stakeholders regarding fatty liver. Thus, MAFLD may renovate clinical practice and disease awareness of fatty liver. In this review, we introduce the definition of and rationale for MAFLD. We further describe representative cases showing how the diagnostic processes differ between MAFLD and NAFLD. We also summarize recent studies comparing MAFLD with NAFLD and discuss the impact of MAFLD on clinical trials, Japanese populations, and disease awareness.
Recently, international expert panels have proposed a new definition of fatty liver: metabolic dysfunction‐associated fatty liver disease (MAFLD). MAFLD is not just a simple renaming of non‐alcoholic fatty liver disease (NAFLD). The unique feature of MAFLD is the inclusion of metabolic dysfunctions, which are high‐risk factors for events. In addition, MAFLD is independent of alcohol intake and the co‐existing causes of liver disease. This new concept of MAFLD may have a widespread impact on patients, medical doctors, medical staff, and various stakeholders regarding fatty liver. Thus, MAFLD may renovate clinical practice and disease awareness of fatty liver. In this review, we introduce the definition of and rationale for MAFLD. We further describe representative cases showing how the diagnostic processes differ between MAFLD and NAFLD. We also summarize recent studies comparing MAFLD with NAFLD and discuss the impact of MAFLD on clinical trials, Japanese populations, and disease awareness.
Author Kawaguchi, Takumi
Nakano, Dan
Torimura, Takuji
Tsutsumi, Tsubasa
Author_xml – sequence: 1
  givenname: Takumi
  orcidid: 0000-0002-7064-4325
  surname: Kawaguchi
  fullname: Kawaguchi, Takumi
  email: takumi@med.kurume-u.ac.jp
  organization: Kurume University School of Medicine
– sequence: 2
  givenname: Tsubasa
  surname: Tsutsumi
  fullname: Tsutsumi, Tsubasa
  organization: Kurume University School of Medicine
– sequence: 3
  givenname: Dan
  surname: Nakano
  fullname: Nakano, Dan
  organization: Kurume University School of Medicine
– sequence: 4
  givenname: Takuji
  surname: Torimura
  fullname: Torimura, Takuji
  organization: Kurume University School of Medicine
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34472683$$D View this record in MEDLINE/PubMed
BookMark eNp9kU1LJDEQhoMofq0Xf4A0eBGh3Xx0PtrboI4ujrjILngL6XQFIz3pMelR5t-bmdE9iGxdqg7PW1W87x7aDH0AhA4JPiO5fj7BLJ4RJrHYQLtESVpiVj1u5pkpUQpWiR20l9IzxkRiWm2jHVZVkgrFdtHt3Wg8uTwvHiD0r2bwfSh6V9jOB29NV8yisYO3UJjQFq1PYFKe30yEACktUWeGYVF0_hXiD7TlTJfg4KPvo7_jqz8XN-Xk_vrXxWhS2nxWlE4RWhPuVMNUw5u2tkRKoZRjrlZgpCC1tJxSzltOGW3B1TUXguFKQNU4w_bRyXrvLPYvc0iDnvpkoetMgH6eNOVCcVWzimT0-Av63M9jyN9pKoSQvM7XMnX0Qc2bKbR6Fv3UxIX-tCkDp2vAxj6lCO4fQrBeZqCXGehVBhnGX2Drh5W1QzS--15C1pI338HiP8v1zdXvh7XmHSF5low
CitedBy_id crossref_primary_10_31083_j_rcm2406157
crossref_primary_10_1111_hepr_14020
crossref_primary_10_3389_fendo_2023_1252774
crossref_primary_10_3390_biomedicines11041097
crossref_primary_10_1016_j_biopha_2023_115279
crossref_primary_10_1111_hepr_13897
crossref_primary_10_1111_hepr_13898
crossref_primary_10_1007_s11901_023_00620_9
crossref_primary_10_1111_hepr_13973
crossref_primary_10_1111_hepr_13808
crossref_primary_10_2147_DMSO_S489692
crossref_primary_10_1111_hepr_13928
crossref_primary_10_1002_jgh3_12898
crossref_primary_10_4014_jmb_2405_05023
crossref_primary_10_3389_fendo_2024_1406793
crossref_primary_10_1038_s41598_025_91312_5
crossref_primary_10_1111_hepr_14010
crossref_primary_10_1111_jgh_16154
crossref_primary_10_1111_hepr_14011
crossref_primary_10_1007_s11739_023_03203_0
crossref_primary_10_1007_s12072_023_10620_y
crossref_primary_10_1111_hepr_13843
crossref_primary_10_3350_cmh_2024_0372
crossref_primary_10_1007_s12072_021_10281_9
crossref_primary_10_1016_j_ejphar_2023_175788
crossref_primary_10_1177_20420188221145549
crossref_primary_10_33326_26176068_2021_4_1259
crossref_primary_10_1016_j_clnesp_2023_10_001
crossref_primary_10_1111_hepr_13912
crossref_primary_10_1002_jcsm_13099
crossref_primary_10_1186_s12876_023_02851_y
crossref_primary_10_3389_fgene_2023_1213916
crossref_primary_10_4254_wjh_v14_i6_1087
crossref_primary_10_1016_j_intimp_2024_112821
crossref_primary_10_3390_jcm11030878
crossref_primary_10_1007_s00535_024_02158_z
crossref_primary_10_3390_cimb47010051
crossref_primary_10_23736_S0031_0808_23_04850_4
crossref_primary_10_3389_fendo_2024_1384059
crossref_primary_10_3350_cmh_2022_0367
crossref_primary_10_1111_hepr_13830
crossref_primary_10_1186_s12889_024_20851_9
crossref_primary_10_3390_nu15051123
crossref_primary_10_1111_hepr_13795
crossref_primary_10_1111_hepr_13993
crossref_primary_10_2169_internalmedicine_4337_24
crossref_primary_10_1111_jdi_13966
crossref_primary_10_1016_j_clinre_2022_102063
crossref_primary_10_1111_hepr_13906
crossref_primary_10_1093_gastro_goad054
crossref_primary_10_1111_hepr_13989
crossref_primary_10_2957_kanzo_64_33
crossref_primary_10_1007_s43032_024_01537_4
crossref_primary_10_1007_s12072_024_10662_w
crossref_primary_10_1016_j_aohep_2024_101750
crossref_primary_10_2169_internalmedicine_3112_23
crossref_primary_10_1039_D3FO04957D
crossref_primary_10_1097_IM9_0000000000000089
crossref_primary_10_2739_kurumemedj_MS7012010
crossref_primary_10_3390_nu15183878
crossref_primary_10_1007_s00535_024_02122_x
crossref_primary_10_3350_cmh_2021_0310
crossref_primary_10_1111_hepr_13738
crossref_primary_10_3390_cells14060428
crossref_primary_10_1111_hepr_13935
crossref_primary_10_1007_s12011_023_03666_4
crossref_primary_10_1007_s10620_022_07508_6
crossref_primary_10_1186_s13098_022_00887_w
crossref_primary_10_3390_metabo14010052
crossref_primary_10_1007_s12072_024_10731_0
crossref_primary_10_3748_wjg_v28_i25_2890
crossref_primary_10_3389_fendo_2022_934225
Cites_doi 10.1111/hepr.12648
10.1007/s00592-021-01677-y
10.1038/nrgastro.2017.109
10.1111/hepr.13540
10.1016/j.jhep.2021.04.021
10.1128/CMR.00046-19
10.1053/j.gastro.2019.11.312
10.1007/s00535-019-01628-z
10.1038/s41575-021-00495-5
10.1111/liv.13391
10.1007/s00535-019-01650-1
10.1002/hep4.1637
10.1016/j.jhep.2021.05.008
10.5009/gnl15163
10.1007/s40264-018-00790-2
10.1016/S2468-1253(20)30340-X
10.1053/j.gastro.2012.04.001
10.1111/hepr.13362
10.3390/ijms21124337
10.1002/hep.30857
10.1053/j.gastro.2020.01.043
10.1111/hepr.12511
10.1111/hepr.12407
10.3390/ijms22115462
10.1007/s00535-012-0647-3
10.2169/internalmedicine.56.7830
10.1016/S0140-6736(20)32511-3
10.1038/s41395-018-0170-0
10.1016/j.metabol.2020.154439
10.1016/j.jhep.2018.10.033
10.1111/liv.14548
10.1007/s12072-021-10157-y
10.1016/S0140-6736(03)15268-3
10.1016/j.cgh.2021.05.029
10.1111/hepr.12665
10.1038/jhg.2014.17
10.1016/j.cgh.2020.12.022
10.1016/j.jhep.2020.03.039
10.2147/DMSO.S217597
10.1111/hepr.13583
10.1016/j.jhep.2021.05.028
10.1371/journal.pone.0245762
10.1136/gutjnl-2021-325102
10.1002/hep.28374
10.1053/j.gastro.2020.12.003
10.1111/hepr.13677
10.2169/internalmedicine.50.5474
10.1002/hep.31420
10.1111/liv.14828
10.1007/s00535-011-0370-5
10.1111/liv.14664
10.1007/s00439-013-1294-3
10.1136/gutjnl-2020-322786
10.14309/ajg.0000000000000607
10.1007/s00535-015-1116-6
10.1007/s12072-020-10094-2
10.1111/liv.14675
10.1007/s11606-019-05340-9
10.2307/2531734
10.1016/j.nut.2020.111080
10.1111/hepr.13570
10.1002/hep.30226
10.1111/joim.13035
10.1056/NEJMra1715733
10.1016/j.metabol.2020.154433
10.1016/j.jhep.2014.08.003
10.1111/hepr.12552
10.1111/hepr.13502
10.1053/jhep.2003.50193
10.1111/jgh.15172
10.1111/hepr.13436
10.1053/j.gastro.2015.04.043
10.1002/hep.30170
10.1111/liv.14788
10.1111/hepr.13282
10.1111/apt.15976
10.1111/hepr.13685
10.1111/liv.13397
10.1016/S2468-1253(20)30213-2
10.1016/j.jhep.2020.12.035
10.1016/j.cgh.2018.07.006
10.1056/NEJMra1503519
10.1371/journal.pone.0132640
10.1371/journal.pone.0140427
10.1002/hep.25772
10.1371/journal.pone.0038322
10.1111/hepr.13572
10.1016/j.jhep.2020.06.016
10.1111/hepr.12840
10.14309/ajg.0000000000000153
10.1111/hepr.13628
10.1111/hepr.12883
ContentType Journal Article
Copyright 2021 Japan Society of Hepatology.
2022 The Japan Society of Hepatology.
Copyright_xml – notice: 2021 Japan Society of Hepatology.
– notice: 2022 The Japan Society of Hepatology.
DBID AAYXX
CITATION
NPM
7T5
7TM
7U9
H94
7X8
DOI 10.1111/hepr.13706
DatabaseName CrossRef
PubMed
Immunology Abstracts
Nucleic Acids Abstracts
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
AIDS and Cancer Research Abstracts
Immunology Abstracts
Virology and AIDS Abstracts
Nucleic Acids Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
CrossRef
PubMed
AIDS and Cancer Research Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1872-034X
EndPage 432
ExternalDocumentID 34472683
10_1111_hepr_13706
HEPR13706
Genre reviewArticle
Journal Article
Review
GrantInformation_xml – fundername: Mitsubishi Tanabe Pharma Corporation
– fundername: Japan Agency for Medical Research and Development
  funderid: JP21fk0210090
– fundername: Otsuka Pharmaceutical
– fundername: Japan Agency for Medical Research and Development
  grantid: JP21fk0210090.
– fundername: Japan Agency for Medical Research and Development
  grantid: JP21fk0210090
GroupedDBID ---
--K
.3N
.GA
.Y3
05W
0R~
10A
1B1
1OC
1~5
29I
31~
33P
3SF
4.4
4G.
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
7-5
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAEDT
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AALRI
AAMNL
AANHP
AANLZ
AAONW
AAQFI
AAQXK
AASGY
AAXRX
AAXUO
AAYCA
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABIJN
ABJNI
ABPVW
ABQWH
ABWVN
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACGOF
ACIUM
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACUHS
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADMUD
ADNMO
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFWVQ
AFZJQ
AHBTC
AIACR
AIAGR
AITUG
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBD
EBS
EJD
ESX
EX3
F00
F01
F04
F5P
FDB
FEDTE
FGOYB
FUBAC
G-Q
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M41
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NQ-
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
Q.N
Q11
QB0
R.K
R2-
RIG
ROL
RPZ
RX1
SEW
SSZ
SUPJJ
TEORI
TUS
UB1
UHS
V8K
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WRC
WVDHM
WXI
WXSBR
XG1
ZZTAW
~IA
~WT
AAYXX
ACVFH
ADCNI
AEUPX
AEYWJ
AFPUW
AGHNM
AGQPQ
AGYGG
AIGII
CITATION
NPM
7T5
7TM
7U9
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
H94
7X8
ID FETCH-LOGICAL-c4476-f812915f8b38b5bd9c177688f3f98ea76197c52255d5232def995663046e4bfa3
IEDL.DBID DR2
ISSN 1386-6346
IngestDate Fri Jul 11 05:02:30 EDT 2025
Mon Jul 14 08:17:06 EDT 2025
Wed Feb 19 02:25:24 EST 2025
Thu Apr 24 23:05:53 EDT 2025
Tue Jul 01 01:58:24 EDT 2025
Wed Jan 22 16:25:06 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords metabolic-associated fatty liver
atherosclerotic cardiovascular disease
disease awareness
hepatic fibrosis
steatosis
Language English
License 2021 Japan Society of Hepatology.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4476-f812915f8b38b5bd9c177688f3f98ea76197c52255d5232def995663046e4bfa3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0002-7064-4325
PMID 34472683
PQID 2666759619
PQPubID 2045151
PageCount 11
ParticipantIDs proquest_miscellaneous_2568589341
proquest_journals_2666759619
pubmed_primary_34472683
crossref_primary_10_1111_hepr_13706
crossref_citationtrail_10_1111_hepr_13706
wiley_primary_10_1111_hepr_13706_HEPR13706
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate May 2022
PublicationDateYYYYMMDD 2022-05-01
PublicationDate_xml – month: 05
  year: 2022
  text: May 2022
PublicationDecade 2020
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
– name: Hoboken
PublicationTitle Hepatology research
PublicationTitleAlternate Hepatol Res
PublicationYear 2022
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2004; 363
2021; 22
2015; 149
2017; 47
2019; 17
2021; 160
2020; 14
2020; 13
2020; 287
2020; 55
2012; 56
2014; 61
2021; 74
2021; 73
2021; 70
2021; 36
2015; 45
2021; 75
2017; 37
2020; 52
2021; 115
2020; 50
2018; 379
2019; 69
1988; 44
2014; 59
2019; 114
2021; 397
2021; 83
2021; 41
2016; 46
2012; 142
2021; 6
2021; 5
2013; 48
2019; 70
2020; 40
2019; 34
2015; 10
2016; 10
2003; 37
2016; 51
2020; 33
2017; 377
2021; 51
2021; 58
2021; 16
2021; 15
2021; 11
2019; 42
2021
2020; 73
2020
2018; 113
2020; 71
2017; 56
2011; 50
2020; 115
2019; 49
2016; 63
2011; 46
2013; 132
2020; 21
2020; 158
2012; 7
2018; 15
e_1_2_18_81_1
e_1_2_18_60_1
e_1_2_18_22_1
e_1_2_18_45_1
e_1_2_18_68_1
e_1_2_18_24_1
e_1_2_18_43_1
e_1_2_18_66_1
e_1_2_18_3_1
e_1_2_18_41_1
e_1_2_18_64_1
e_1_2_18_5_1
e_1_2_18_20_1
e_1_2_18_62_1
e_1_2_18_7_1
e_1_2_18_83_1
e_1_2_18_9_1
e_1_2_18_85_1
e_1_2_18_26_1
e_1_2_18_49_1
e_1_2_18_87_1
e_1_2_18_28_1
e_1_2_18_47_1
e_1_2_18_89_1
e_1_2_18_90_1
e_1_2_18_92_1
e_1_2_18_71_1
e_1_2_18_10_1
e_1_2_18_33_1
e_1_2_18_56_1
e_1_2_18_79_1
e_1_2_18_12_1
e_1_2_18_35_1
e_1_2_18_54_1
e_1_2_18_77_1
Wong VWS (e_1_2_18_58_1) 2020
e_1_2_18_52_1
e_1_2_18_75_1
e_1_2_18_31_1
e_1_2_18_50_1
e_1_2_18_73_1
e_1_2_18_94_1
e_1_2_18_14_1
e_1_2_18_37_1
e_1_2_18_39_1
e_1_2_18_16_1
e_1_2_18_80_1
e_1_2_18_82_1
e_1_2_18_2_1
e_1_2_18_21_1
e_1_2_18_46_1
e_1_2_18_67_1
e_1_2_18_4_1
e_1_2_18_23_1
e_1_2_18_44_1
e_1_2_18_65_1
e_1_2_18_6_1
e_1_2_18_42_1
e_1_2_18_63_1
e_1_2_18_8_1
e_1_2_18_40_1
e_1_2_18_61_1
Sumida Y (e_1_2_18_18_1) 2021; 11
e_1_2_18_29_1
e_1_2_18_84_1
e_1_2_18_86_1
e_1_2_18_25_1
e_1_2_18_88_1
e_1_2_18_27_1
e_1_2_18_48_1
e_1_2_18_69_1
e_1_2_18_91_1
e_1_2_18_93_1
e_1_2_18_70_1
e_1_2_18_11_1
e_1_2_18_32_1
e_1_2_18_57_1
e_1_2_18_78_1
e_1_2_18_13_1
e_1_2_18_34_1
e_1_2_18_55_1
e_1_2_18_76_1
e_1_2_18_53_1
e_1_2_18_74_1
e_1_2_18_30_1
e_1_2_18_51_1
e_1_2_18_72_1
e_1_2_18_19_1
e_1_2_18_95_1
e_1_2_18_15_1
e_1_2_18_36_1
e_1_2_18_17_1
e_1_2_18_38_1
e_1_2_18_59_1
References_xml – volume: 115
  year: 2021
  article-title: Moderate alcohol consumption is associated with advanced fibrosis in non‐alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus
  publication-title: Metabolism
– volume: 52
  start-page: 866
  year: 2020
  end-page: 76
  article-title: Association between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C elimination
  publication-title: Aliment Pharmacol Ther
– volume: 142
  start-page: 1592
  year: 2012
  end-page: 609
  article-title: The diagnosis and management of non‐alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology
  publication-title: Gastroenterology
– volume: 51
  start-page: 62
  year: 2021
  end-page: 8
  article-title: Effects of alcohol consumption on multiple hepatocarcinogenesis in patients with fatty liver disease
  publication-title: Hepatol Res
– volume: 55
  start-page: 363
  year: 2020
  end-page: 4
  article-title: Is metabolic syndrome responsible for the progression from NAFLD to NASH in non‐obese patients?
  publication-title: J Gastroenterol
– volume: 15
  start-page: 380
  year: 2021
  end-page: 91
  article-title: Does the risk of cardiovascular events differ between biopsy‐proven NAFLD and MAFLD?
  publication-title: Hepatol Int
– volume: 45
  start-page: 728
  year: 2015
  end-page: 38
  article-title: Predictors of malignancies and overall mortality in Japanese patients with biopsy‐proven non‐alcoholic fatty liver disease
  publication-title: Hepatol Res
– volume: 115
  year: 2021
  article-title: MAFLD and risk of CKD
  publication-title: Metabolism
– volume: 379
  start-page: 1251
  year: 2018
  end-page: 61
  article-title: Alcohol use in patients with chronic liver disease
  publication-title: N Engl J Med
– volume: 50
  start-page: 1015
  year: 2020
  end-page: 23
  article-title: Liver disease in pregnancy
  publication-title: Hepatol Res
– volume: 49
  start-page: 1114
  year: 2019
  end-page: 20
  article-title: Real‐world efficacy of elbasvir and grazoprevir for hepatitis C virus (genotype 1): a nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group
  publication-title: Hepatol Res
– volume: 10
  year: 2015
  article-title: The impact of PNPLA3 rs738409 genetic polymorphism and weight gain >/=10 kg after age 20 on non‐alcoholic fatty liver disease in non‐obese Japanese individuals
  publication-title: PLoS One
– volume: 363
  start-page: 157
  year: 2004
  end-page: 63
  article-title: Appropriate body‐mass index for Asian populations and its implications for policy and intervention strategies
  publication-title: Lancet
– volume: 5
  start-page: 559
  year: 2021
  end-page: 72
  article-title: Type IV Collagen 7S is the most accurate test for identifying advanced fibrosis in NAFLD with type 2 diabetes
  publication-title: Hepatol Commun
– volume: 10
  start-page: 437
  year: 2016
  end-page: 45
  article-title: Relationships between genetic variations of PNPLA3, TM6SF2 and histological features of nonalcoholic fatty liver disease in Japan
  publication-title: Gut Liver
– volume: 46
  start-page: E146
  year: 2016
  end-page: 53
  article-title: Influence of the rs738409 polymorphism in patatin‐like phospholipase 3 on the treatment efficacy of non‐alcoholic fatty liver disease with type 2 diabetes mellitus
  publication-title: Hepatol Res
– volume: 73
  start-page: 1265
  year: 2020
  end-page: 7
  article-title: MAFLD criteria overlooks a number of patients with severe steatosis: is it clinically relevant?
  publication-title: J Hepatol
– volume: 56
  start-page: 943
  year: 2012
  end-page: 51
  article-title: Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis
  publication-title: Hepatology
– volume: 37
  start-page: 1202
  year: 2003
  end-page: 19
  article-title: Nonalcoholic steatohepatitis: summary of an AASLD single topic conference
  publication-title: Hepatology
– volume: 59
  start-page: 241
  year: 2014
  end-page: 6
  article-title: Targeted next‐generation sequencing and fine linkage disequilibrium mapping reveals association of PNPLA3 and PARVB with the severity of nonalcoholic fatty liver disease
  publication-title: J Hum Genet
– volume: 70
  start-page: 531
  year: 2019
  end-page: 44
  article-title: Non‐alcoholic fatty liver disease – a global public health perspective
  publication-title: J Hepatol
– volume: 7
  year: 2012
  article-title: Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non‐alcoholic fatty liver disease in Japanese
  publication-title: PLoS One
– year: 2021
  article-title: Novel artificial intelligent/neural network system for staging of nonalcoholic steatohepatitis
  publication-title: Hepatol Res
– volume: 377
  start-page: 2063
  year: 2017
  end-page: 72
  article-title: Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis
  publication-title: N Engl J Med
– volume: 44
  start-page: 1049
  year: 1988
  end-page: 60
  article-title: Models for longitudinal data: a generalized estimating equation approach
  publication-title: Biometrics
– year: 2021
  article-title: Long‐term outcomes and predictive ability of non‐invasive scoring systems in patients with non‐alcoholic fatty liver disease
  publication-title: J Hepatol
– volume: 33
  year: 2020
  end-page: 19
  article-title: Hepatitis B virus: advances in prevention, diagnosis, and therapy
  publication-title: Clin Microbiol Rev
– volume: 47
  start-page: 1083
  year: 2017
  end-page: 92
  article-title: Development of hepatocellular carcinoma in Japanese patients with biopsy‐proven non‐alcoholic fatty liver disease: association between PNPLA3 genotype and hepatocarcinogenesis/fibrosis progression
  publication-title: Hepatol Res
– volume: 51
  start-page: 19
  year: 2021
  end-page: 30
  article-title: Hepatocellular carcinoma and other complications of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in Japan: a structured review of published works
  publication-title: Hepatol Res
– volume: 114
  start-page: 916
  year: 2019
  end-page: 28
  article-title: Impact of obesity and alanine aminotransferase levels on the diagnostic accuracy for advanced liver fibrosis of noninvasive tools in patients with nonalcoholic fatty liver disease
  publication-title: Am J Gastroenterol
– volume: 13
  start-page: 333
  year: 2020
  end-page: 41
  article-title: A pilot study assessing the possible combined effect of physical activity and PNPLA3 rs738409 polymorphism on the risk for non‐alcoholic fatty liver disease in the Japanese elderly general population
  publication-title: Diabetes Metab Syndr Obes
– volume: 160
  start-page: 1608
  year: 2021
  end-page: 19
  article-title: The association of histologic and noninvasive tests with adverse clinical and patient‐reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis
  publication-title: Gastroenterology
– volume: 6
  start-page: 65
  year: 2021
  end-page: 72
  article-title: The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease
  publication-title: Lancet Gastroenterol Hepatol
– volume: 14
  start-page: 889
  year: 2020
  end-page: 919
  article-title: The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
  publication-title: Hepatol Int
– volume: 55
  start-page: 330
  year: 2020
  end-page: 41
  article-title: Association between body size‐metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis
  publication-title: J Gastroenterol
– year: 2021
  article-title: Diabetes is the strongest risk factor of hepatic fibrosis in lean patients with non‐alcoholic fatty liver disease
  publication-title: Gut
– volume: 132
  start-page: 783
  year: 2013
  end-page: 92
  article-title: Genome‐wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan
  publication-title: Hum Genet
– volume: 37
  start-page: 1389
  year: 2017
  end-page: 96
  article-title: Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: an age‐dependent risk profiling study
  publication-title: Liver Int
– volume: 22
  start-page: 5462
  year: 2021
  article-title: Non‐obese MAFLD is associated with colorectal adenoma in health check examinees: a multicenter retrospective study
  publication-title: Int J Mol Sci
– volume: 21
  start-page: 4337
  year: 2020
  article-title: Epidemiology: pathogenesis, and diagnostic strategy of diabetic liver disease in Japan
  publication-title: Int J Mol Sci
– volume: 69
  start-page: 64
  year: 2019
  end-page: 75
  article-title: Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease: a cohort study
  publication-title: Hepatology
– volume: 42
  start-page: 701
  year: 2019
  end-page: 11
  article-title: Drug‐induced steatosis and steatohepatitis: the search for novel serum biomarkers among potential biomarkers for non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis
  publication-title: Drug Saf
– volume: 75
  start-page: 221
  year: 2021
  end-page: 2
  article-title: Redefinition of fatty liver disease from NAFLD to MAFLD raised disease awareness: Mexican experience
  publication-title: J Hepatol
– volume: 34
  start-page: 2772
  year: 2019
  end-page: 8
  article-title: Low awareness of nonalcoholic fatty liver disease in a population‐based cohort sample: the CARDIA study
  publication-title: J Gen Intern Med
– volume: 113
  start-page: 1409
  year: 2018
  end-page: 11
  article-title: Non‐invasive diagnosis of nonalcoholic fatty liver disease
  publication-title: Am J Gastroenterol
– volume: 83
  year: 2021
  article-title: Development and course of diabetes according to genetic factors and diabetes treatment among patients with nonalcoholic fatty liver disease
  publication-title: Nutrition
– year: 2021
  article-title: NAFLD early in life associated with increased long‐term mortality
  publication-title: Nat Rev Gastroenterol Hepatol
– volume: 58
  start-page: 651
  year: 2021
  end-page: 5
  article-title: Lack of awareness of liver organ damage in patients with type 2 diabetes
  publication-title: Acta Diabetol
– volume: 16
  year: 2021
  article-title: Outcomes of NAFLD and MAFLD: results from a community‐based, prospective cohort study
  publication-title: PLoS One
– volume: 48
  start-page: 405
  year: 2013
  end-page: 12
  article-title: The impact of patatin‐like phospholipase domain‐containing protein 3 polymorphism on hepatocellular carcinoma prognosis
  publication-title: J Gastroenterol
– volume: 10
  year: 2015
  article-title: Influence of the PNPLA3 rs738409 polymorphism on non‐alcoholic fatty liver disease and renal function among normal weight subjects
  publication-title: PLoS One
– volume: 149
  start-page: 389
  year: 2015
  end-page: 97
  article-title: Liver fibrosis, but no other histologic features, is associated with long‐term outcomes of patients with nonalcoholic fatty liver disease
  publication-title: Gastroenterology
– volume: 41
  start-page: 683
  year: 2021
  end-page: 91
  article-title: From NAFLD to MAFLD: nurse and allied health perspective
  publication-title: Liver Int
– volume: 11
  year: 2021
  article-title: FIB‐4 first in the diagnostic algorithm of metabolic‐dysfunction‐associated fatty liver disease in the era of the global metabodemic
  publication-title: Life (Basel)
– volume: 51
  start-page: 90
  year: 2021
  end-page: 101
  article-title: Non‐invasive fibrosis markers are associated with mortality risk in both general populations and non‐alcoholic fatty liver disease patients
  publication-title: Hepatol Res
– year: 2020
  article-title: Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease
  publication-title: Clin Gastroenterol Hepatol
– volume: 40
  start-page: 2082
  year: 2020
  end-page: 9
  article-title: Comparison of MAFLD and NAFLD diagnostic criteria in real world
  publication-title: Liver Int
– volume: 46
  start-page: 1011
  year: 2016
  end-page: 18
  article-title: Characteristics of non‐obese non‐alcoholic fatty liver disease: effect of genetic and environmental factors
  publication-title: Hepatol Res
– volume: 36
  start-page: 629
  year: 2021
  end-page: 36
  article-title: Patient‐reported outcomes in patients with non‐alcoholic fatty liver disease: a narrative review of Chronic Liver Disease Questionnaire‐non‐alcoholic fatty liver disease/non‐alcoholic steatohepatitis
  publication-title: J Gastroenterol Hepatol
– volume: 46
  start-page: 1107
  year: 2016
  end-page: 17
  article-title: Association of coronary artery calcification with liver fibrosis in Japanese patients with non‐alcoholic fatty liver disease
  publication-title: Hepatol Res
– volume: 71
  start-page: 539
  year: 2020
  end-page: 48
  article-title: Nonalcoholic steatohepatitis is associated with liver‐related outcomes and all‐cause mortality in chronic hepatitis B
  publication-title: Hepatology
– year: 2021
  article-title: Impact of direct‐acting antivirals for HCV on mortality in a large population‐based cohort study
  publication-title: J Hepatol
– volume: 61
  start-page: S69
  year: 2014
  end-page: 78
  article-title: Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases
  publication-title: J Hepatol
– volume: 41
  start-page: 1290
  year: 2021
  end-page: 3
  article-title: Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population
  publication-title: Liver Int
– volume: 73
  start-page: 1194
  year: 2021
  end-page: 8
  article-title: From NAFLD to MAFLD: implications of a premature change in terminology
  publication-title: Hepatology
– year: 2020
  article-title: Metabolic dysfunction‐associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study
  publication-title: Clin Gastroenterol Hepatol
– volume: 115
  start-page: 876
  year: 2020
  end-page: 84
  article-title: Light‐to‐moderate alcohol consumption is associated with increased risk of type 2 diabetes in individuals with nonalcoholic fatty liver disease: a nine‐year cohort study
  publication-title: Am J Gastroenterol
– volume: 73
  start-page: 202
  year: 2020
  end-page: 9
  article-title: A new definition for metabolic dysfunction‐associated fatty liver disease: an international expert consensus statement
  publication-title: J Hepatol
– volume: 51
  start-page: 860
  issue: 8
  year: 2021
  end-page: 9
  article-title: Association of liver stiffness and steatosis with hepatocellular carcinoma development in patients with hepatitis C virus infection who received direct‐acting antiviral therapy and achieved sustained virological response
  publication-title: Hepatol Res
– volume: 47
  start-page: 1459
  year: 2017
  end-page: 68
  article-title: Hepatic nucleotide binding oligomerization domain‐like receptors pyrin domain‐containing 3 inflammasomes are associated with the histologic severity of non‐alcoholic fatty liver disease
  publication-title: Hepatol Res
– volume: 63
  start-page: 745
  year: 2016
  end-page: 53
  article-title: Portal inflammation is independently associated with fibrosis and metabolic syndrome in pediatric nonalcoholic fatty liver disease
  publication-title: Hepatology
– volume: 51
  start-page: 370
  year: 2016
  end-page: 9
  article-title: The impact of PNPLA3 and JAZF1 on hepatocellular carcinoma in non‐viral hepatitis patients with type 2 diabetes mellitus
  publication-title: J Gastroenterol
– volume: 287
  start-page: 711
  year: 2020
  end-page: 22
  article-title: Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011‐2016
  publication-title: J Intern Med
– volume: 40
  start-page: 3018
  year: 2020
  end-page: 30
  article-title: MAFLD identifies patients with significant hepatic fibrosis better than NAFLD
  publication-title: Liver Int
– volume: 46
  start-page: 758
  year: 2011
  end-page: 68
  article-title: Clinical characteristics of de novo nonalcoholic fatty liver disease following pancreaticoduodenectomy
  publication-title: J Gastroenterol
– volume: 45
  start-page: 363
  year: 2015
  end-page: 77
  article-title: Evidence‐based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
  publication-title: Hepatol Res
– volume: 56
  start-page: 1459
  year: 2017
  end-page: 65
  article-title: New discriminant method for identifying the aggressive disease phenotype of non‐alcoholic fatty liver disease
  publication-title: Intern Med
– volume: 40
  start-page: 3145
  year: 2020
  article-title: Response to: comparison of MAFLD and NAFLD diagnostic criteria in real world
  publication-title: Liver Int
– volume: 158
  start-page: 1999
  year: 2020
  end-page: 2014
  article-title: MAFLD: a consensus‐driven proposed nomenclature for metabolic associated fatty liver disease
  publication-title: Gastroenterology
– volume: 50
  start-page: 1911
  year: 2011
  end-page: 16
  article-title: Influence of obesity on control in asthmatic Japanese patients defined by the Japanese definition of obesity
  publication-title: Intern Med
– volume: 37
  start-page: 1209
  year: 2017
  end-page: 18
  article-title: A disease‐specific quality of life instrument for non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis: CLDQ‐NAFLD
  publication-title: Liver Int
– volume: 50
  start-page: 645
  year: 2020
  end-page: 55
  article-title: Non‐invasive diagnosis of non‐alcoholic steatohepatitis and advanced fibrosis in Japan: a targeted literature review
  publication-title: Hepatol Res
– volume: 6
  start-page: 57
  year: 2021
  end-page: 64
  article-title: Nomenclature and definition of metabolic‐associated fatty liver disease: a consensus from the Middle East and North Africa
  publication-title: Lancet Gastroenterol Hepatol
– volume: 397
  start-page: 2212
  year: 2021
  end-page: 24
  article-title: Non‐alcoholic fatty liver disease
  publication-title: Lancet
– volume: 49
  start-page: 296
  year: 2019
  end-page: 303
  article-title: Epidemiological survey of hemoglobin A1c and liver fibrosis in a general population with non‐alcoholic fatty liver disease
  publication-title: Hepatol Res
– volume: 50
  start-page: 199
  year: 2020
  end-page: 213
  article-title: Profiles of advanced hepatic fibrosis evaluated by FIB‐4 index and shear wave elastography in health checkup examinees
  publication-title: Hepatol Res
– volume: 70
  start-page: 1375
  year: 2021
  end-page: 82
  article-title: Mortality in biopsy‐confirmed nonalcoholic fatty liver disease: results from a nationwide cohort
  publication-title: Gut
– volume: 17
  start-page: 543
  year: 2019
  end-page: 50
  article-title: Obesity and weight gain are associated with progression of fibrosis in patients with nonalcoholic fatty liver disease
  publication-title: Clin Gastroenterol Hepatol
– year: 2021
  article-title: Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD
  publication-title: Clin Gastroenterol Hepatol
– volume: 70
  start-page: 511
  year: 2019
  end-page: 21
  article-title: Effect of alcohol consumption on survival in nonalcoholic fatty liver disease: a National Prospective Cohort Study
  publication-title: Hepatology
– year: 2021
  article-title: MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach
  publication-title: Hepatol Res
– volume: 15
  start-page: 11
  year: 2018
  end-page: 20
  article-title: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
  publication-title: Nat Rev Gastroenterol Hepatol
– volume: 158
  start-page: 1611
  year: 2020
  end-page: 25
  article-title: Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta‐analysis
  publication-title: Gastroenterology
– volume: 74
  start-page: 1254
  year: 2021
  end-page: 6
  article-title: Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists
  publication-title: J Hepatol
– ident: e_1_2_18_77_1
  doi: 10.1111/hepr.12648
– ident: e_1_2_18_90_1
  doi: 10.1007/s00592-021-01677-y
– ident: e_1_2_18_3_1
  doi: 10.1038/nrgastro.2017.109
– ident: e_1_2_18_40_1
  doi: 10.1111/hepr.13540
– ident: e_1_2_18_95_1
  doi: 10.1016/j.jhep.2021.04.021
– ident: e_1_2_18_48_1
  doi: 10.1128/CMR.00046-19
– ident: e_1_2_18_68_1
  doi: 10.1053/j.gastro.2019.11.312
– ident: e_1_2_18_26_1
  doi: 10.1007/s00535-019-01628-z
– ident: e_1_2_18_9_1
  doi: 10.1038/s41575-021-00495-5
– ident: e_1_2_18_89_1
  doi: 10.1111/liv.13391
– ident: e_1_2_18_27_1
  doi: 10.1007/s00535-019-01650-1
– ident: e_1_2_18_19_1
  doi: 10.1002/hep4.1637
– ident: e_1_2_18_14_1
  doi: 10.1016/j.jhep.2021.05.008
– ident: e_1_2_18_76_1
  doi: 10.5009/gnl15163
– ident: e_1_2_18_41_1
  doi: 10.1007/s40264-018-00790-2
– ident: e_1_2_18_51_1
  doi: 10.1016/S2468-1253(20)30340-X
– ident: e_1_2_18_45_1
  doi: 10.1053/j.gastro.2012.04.001
– ident: e_1_2_18_46_1
  doi: 10.1111/hepr.13362
– ident: e_1_2_18_4_1
  doi: 10.3390/ijms21124337
– ident: e_1_2_18_38_1
  doi: 10.1002/hep.30857
– ident: e_1_2_18_88_1
  doi: 10.1053/j.gastro.2020.01.043
– ident: e_1_2_18_44_1
  doi: 10.1111/hepr.12511
– ident: e_1_2_18_13_1
  doi: 10.1111/hepr.12407
– ident: e_1_2_18_64_1
  doi: 10.3390/ijms22115462
– ident: e_1_2_18_70_1
  doi: 10.1007/s00535-012-0647-3
– ident: e_1_2_18_80_1
  doi: 10.2169/internalmedicine.56.7830
– ident: e_1_2_18_6_1
  doi: 10.1016/S0140-6736(20)32511-3
– ident: e_1_2_18_16_1
  doi: 10.1038/s41395-018-0170-0
– ident: e_1_2_18_35_1
  doi: 10.1016/j.metabol.2020.154439
– ident: e_1_2_18_2_1
  doi: 10.1016/j.jhep.2018.10.033
– ident: e_1_2_18_56_1
  doi: 10.1111/liv.14548
– ident: e_1_2_18_49_1
  doi: 10.1007/s12072-021-10157-y
– ident: e_1_2_18_84_1
  doi: 10.1016/S0140-6736(03)15268-3
– ident: e_1_2_18_65_1
  doi: 10.1016/j.cgh.2021.05.029
– ident: e_1_2_18_11_1
  doi: 10.1111/hepr.12665
– ident: e_1_2_18_72_1
  doi: 10.1038/jhg.2014.17
– ident: e_1_2_18_61_1
  doi: 10.1016/j.cgh.2020.12.022
– ident: e_1_2_18_20_1
  doi: 10.1016/j.jhep.2020.03.039
– ident: e_1_2_18_83_1
  doi: 10.2147/DMSO.S217597
– ident: e_1_2_18_7_1
  doi: 10.1111/hepr.13583
– ident: e_1_2_18_47_1
  doi: 10.1016/j.jhep.2021.05.028
– ident: e_1_2_18_60_1
  doi: 10.1371/journal.pone.0245762
– ident: e_1_2_18_21_1
  doi: 10.1136/gutjnl-2021-325102
– ident: e_1_2_18_29_1
  doi: 10.1002/hep.28374
– ident: e_1_2_18_86_1
  doi: 10.1053/j.gastro.2020.12.003
– ident: e_1_2_18_36_1
  doi: 10.1111/hepr.13677
– ident: e_1_2_18_85_1
  doi: 10.2169/internalmedicine.50.5474
– ident: e_1_2_18_54_1
  doi: 10.1002/hep.31420
– ident: e_1_2_18_59_1
  doi: 10.1111/liv.14828
– ident: e_1_2_18_43_1
  doi: 10.1007/s00535-011-0370-5
– ident: e_1_2_18_66_1
  doi: 10.1111/liv.14664
– year: 2020
  ident: e_1_2_18_58_1
  article-title: Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease
  publication-title: Clin Gastroenterol Hepatol
– ident: e_1_2_18_71_1
  doi: 10.1007/s00439-013-1294-3
– ident: e_1_2_18_8_1
  doi: 10.1136/gutjnl-2020-322786
– ident: e_1_2_18_31_1
  doi: 10.14309/ajg.0000000000000607
– ident: e_1_2_18_74_1
  doi: 10.1007/s00535-015-1116-6
– ident: e_1_2_18_52_1
  doi: 10.1007/s12072-020-10094-2
– ident: e_1_2_18_57_1
  doi: 10.1111/liv.14675
– ident: e_1_2_18_92_1
  doi: 10.1007/s11606-019-05340-9
– ident: e_1_2_18_67_1
  doi: 10.2307/2531734
– ident: e_1_2_18_81_1
  doi: 10.1016/j.nut.2020.111080
– ident: e_1_2_18_10_1
  doi: 10.1111/hepr.13570
– ident: e_1_2_18_32_1
  doi: 10.1002/hep.30226
– ident: e_1_2_18_91_1
  doi: 10.1111/joim.13035
– ident: e_1_2_18_34_1
  doi: 10.1056/NEJMra1715733
– ident: e_1_2_18_63_1
  doi: 10.1016/j.metabol.2020.154433
– ident: e_1_2_18_39_1
  doi: 10.1016/j.jhep.2014.08.003
– ident: e_1_2_18_82_1
  doi: 10.1111/hepr.12552
– ident: e_1_2_18_17_1
  doi: 10.1111/hepr.13502
– ident: e_1_2_18_53_1
  doi: 10.1053/jhep.2003.50193
– ident: e_1_2_18_87_1
  doi: 10.1111/jgh.15172
– ident: e_1_2_18_5_1
  doi: 10.1111/hepr.13436
– ident: e_1_2_18_12_1
  doi: 10.1053/j.gastro.2015.04.043
– ident: e_1_2_18_33_1
  doi: 10.1002/hep.30170
– ident: e_1_2_18_94_1
  doi: 10.1111/liv.14788
– ident: e_1_2_18_22_1
  doi: 10.1111/hepr.13282
– ident: e_1_2_18_37_1
  doi: 10.1111/apt.15976
– ident: e_1_2_18_62_1
  doi: 10.1111/hepr.13685
– ident: e_1_2_18_28_1
  doi: 10.1111/liv.13397
– ident: e_1_2_18_50_1
  doi: 10.1016/S2468-1253(20)30213-2
– ident: e_1_2_18_93_1
  doi: 10.1016/j.jhep.2020.12.035
– ident: e_1_2_18_24_1
  doi: 10.1016/j.cgh.2018.07.006
– ident: e_1_2_18_42_1
  doi: 10.1056/NEJMra1503519
– ident: e_1_2_18_73_1
  doi: 10.1371/journal.pone.0132640
– volume: 11
  year: 2021
  ident: e_1_2_18_18_1
  article-title: FIB‐4 first in the diagnostic algorithm of metabolic‐dysfunction‐associated fatty liver disease in the era of the global metabodemic
  publication-title: Life (Basel)
– ident: e_1_2_18_75_1
  doi: 10.1371/journal.pone.0140427
– ident: e_1_2_18_25_1
  doi: 10.1002/hep.25772
– ident: e_1_2_18_69_1
  doi: 10.1371/journal.pone.0038322
– ident: e_1_2_18_30_1
  doi: 10.1111/hepr.13572
– ident: e_1_2_18_55_1
  doi: 10.1016/j.jhep.2020.06.016
– ident: e_1_2_18_78_1
  doi: 10.1111/hepr.12840
– ident: e_1_2_18_23_1
  doi: 10.14309/ajg.0000000000000153
– ident: e_1_2_18_15_1
  doi: 10.1111/hepr.13628
– ident: e_1_2_18_79_1
  doi: 10.1111/hepr.12883
SSID ssj0017024
Score 2.5722675
SecondaryResourceType review_article
Snippet Recently, international expert panels have proposed a new definition of fatty liver: metabolic dysfunction‐associated fatty liver disease (MAFLD). MAFLD is not...
Recently, international expert panels have proposed a new definition of fatty liver: metabolic dysfunction-associated fatty liver disease (MAFLD). MAFLD is not...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 422
SubjectTerms Atherosclerosis
atherosclerotic cardiovascular disease
Clinical medicine
Clinical trials
disease awareness
Fatty liver
hepatic fibrosis
Liver diseases
metabolic‐associated fatty liver
Metabolism
Risk factors
steatosis
Title MAFLD: Renovation of clinical practice and disease awareness of fatty liver
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fhepr.13706
https://www.ncbi.nlm.nih.gov/pubmed/34472683
https://www.proquest.com/docview/2666759619
https://www.proquest.com/docview/2568589341
Volume 52
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bSx0xEB5EQfpSb71sqxLRF4U9NCeX3RVfjpfDodVSDgq-lCXJJhSUPaJ7KPXXm8levCLUt4WdJdkkk_kmM_MFYMtxLjJa0Nh68xxzkahYZcbETpqEaSsKqkK2xU85OuPfz8X5DOy1tTA1P0R34IaaEfZrVHClbx4o-R97dd2jLAl825ishYho3HFH0eRbc6NtKmPJuGy4STGN5_7Tx9boGcR8jFiDyRkuwO-2s3WmyUVvWumeuX3C4_jWv1mE9w0WJYN68SzBjC2XYf6kibavwI-TwfD4cJeMbXtzKpk40tZSkrbAiqiyIE2gh6i_WF3mt08Udaqq_pFLTP34AGfDo9ODUdxcvhAbzhMZO2_5MypcqlmqhS4yQxPvmqSOuSy1Ck8_EuPBmxCF92X7hXVYIysx0Gq5dop9hNlyUtrPQLwPrBQVqVTMce-RKkM1tSmVWjAPn7IItttJyE3DTI4XZFzmrYeCo5OH0Ylgs5O9qvk4XpRabecyb3TyJvdQxHtHme94BBvda69NGCJRpZ1MvYxAPv7Mm_YIPtVroGsGuRH7MmUR7ISZfKX9fHT0axyevvyP8Fd418fqipBPuQqz1fXUrnnMU-l1mBvsH-4P18MavwNHxfuY
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VIgGX8oaUAkbAAaSs6viRBIlDxXa1ZXcrtGql3oLt2EKiylZtVlX5T_yV_qaOEydQQEgceuAWKaPY8cx4vrHnAfDKcS5yWtLYonmOuUhVrHJjYidNyrQVJVVNtMWuHO_zjwfiYAW-d7kwbX2I_sDNa0azX3sF9wfSP2n5F3t0PKAs3ZQhpnJiz07RYzt5vzNE9r5OktH23odxHJoKxIbzVMYOLVpOhcs0y7TQZW5oipA7c8zlmVXeq08NghIhSvTRktI6n_sp_QWi5dopht-9Btd9C3Ffqn8476tV0XQz9NDNZCwZl6Eaqg8c-jHXy_bvN1B7GSM3Rm50G8675WljW74OlrUemG-_VI78b9bvDqwFuE22Wv24Cyu2ugc3ZiGg4D5MZluj6fAdmduuOSxZONKli5Iuh4yoqiThLouoU59AhxbCkzpV12fk0Ee3PID9K_mVh7BaLSr7GAi6-UpRkUnFHEenWxmqqc2o1IIhQswjeNNxvTCh-LrvAXJYdE6Y50bRcCOClz3tUVty5I9UG53wFGHbOSkQbaEDmOPEI3jRv8YNw98CqcoulkgjfMuBHNFLBI9aoeuH8eUfE5mxCN42ovOX8Yvx9qd587T-L8TP4eZ4bzYtpju7kydwK_HJJE346Aas1sdL-xQhXq2fNYpF4PNVS-IF1MxVzg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VIlVcoLwDLRgBB5CyWsePxEgcKrarLdtW1YpKvQU7sYVElV21WVXlN_FX-E8dJ05oASFx6IFbpIxixzPj-caeB8Arx7lQtKSxRfMcc5HqWKuiiJ0sUmasKKluoi325eSQfzwSRyvwvcuFaetD9AduXjOa_dor-KJ0l5T8i12cDChLhzKEVE7t-Rk6bKfvd0bI3ddJMt7-9GESh54CccF5KmOHBk1R4TLDMiNMqQqaIuLOHHMqs9o79WmBmESIEl20pLTOp35Kf39ouXGa4XdvwE0uh8o3ihjN-mJVNB2GFrqZjCXjMhRD9XFDP-d61fz9hmmvQuTGxo3vwI9uddrQlq-DZW0GxbdfCkf-L8u3DrcD2CZbrXbchRVb3YO1vRBOcB-me1vj3dE7MrNda1gyd6RLFiVdBhnRVUnCTRbRZz59Du2DJ3W6rs_JsY9teQCH1_IrD2G1mlf2MRB08rWmIpOaOY4uty6ooTaj0giG-FBF8KZjel6E0uu-A8hx3rlgnht5w40IXva0i7bgyB-pNjrZycOmc5oj1kL3T-HEI3jRv8btwt8B6crOl0gjfMMBhdglgketzPXD-OKPicxYBG8byfnL-Plk-2DWPD35F-LnsHYwGue7O_vTp3Ar8ZkkTezoBqzWJ0u7ifiuNs8atSLw-boF8QJXwlR9
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MAFLD%3A+Renovation+of+clinical+practice+and+disease+awareness+of+fatty+liver&rft.jtitle=Hepatology+research&rft.au=Kawaguchi%2C+Takumi&rft.au=Tsutsumi%2C+Tsubasa&rft.au=Nakano%2C+Dan&rft.au=Torimura%2C+Takuji&rft.date=2022-05-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=1386-6346&rft.eissn=1872-034X&rft.volume=52&rft.issue=5&rft.spage=422&rft.epage=432&rft_id=info:doi/10.1111%2Fhepr.13706&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1386-6346&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1386-6346&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1386-6346&client=summon